Subscribe
shutterstock_1155148972_atmosphere1
Atmosphere1 / Shutterstock.com
26 October 2022GenericsStaff Writer

MSD hit with €39m fine over contraceptive generic delay

The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
MSD accuses university of patent contract breach
1 December 2022   Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.
Americas
MSD makes $1.4bn bid on biopharma company
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.
Big Pharma
MSD prevails in diabetes drug dispute with Mylan
29 September 2022   MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Americas
MSD accuses university of patent contract breach
1 December 2022   Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.
Americas
MSD makes $1.4bn bid on biopharma company
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.
Big Pharma
MSD prevails in diabetes drug dispute with Mylan
29 September 2022   MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

More on this story

Americas
MSD accuses university of patent contract breach
1 December 2022   Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.
Americas
MSD makes $1.4bn bid on biopharma company
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.
Big Pharma
MSD prevails in diabetes drug dispute with Mylan
29 September 2022   MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims